Apogee Therapeutics (APGE) Net Income towards Common Stockholders (2022 - 2026)
Apogee Therapeutics (APGE) reported Net Income towards Common Stockholders of -$74.1 million for Q1 2026, down 33.92% year-over-year from -$112.2 million in Q1 2025, and down 6.81% on a QoQ basis from -$69.4 million in Q4 2025.
Apogee Therapeutics (APGE) has 5 years of Net Income towards Common Stockholders data on file, last reported at -$74.1 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 33.92% year-over-year to -$74.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$274.6 million (down 33.7% YoY) and the FY2025 annual result came in at -$255.8 million, down 40.46% from the prior year.
- Net Income towards Common Stockholders retreated to -$74.1 million in Q1 2026 per APGE's latest filing, from -$69.4 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$1.8 million in Q2 2022 and bottomed at -$74.1 million in Q1 2026.
- The 5-year median for Net Income towards Common Stockholders is -$33.0 million (2024), against an average of -$39.5 million.
- The widest annual swing landed in 2023, when Net Income towards Common Stockholders slumped 939.92%; it then fell 3.23% in 2025.
- Tracing APGE's Net Income towards Common Stockholders over 5 years: stood at -$14.0 million in 2022, then tumbled by 126.57% to -$31.7 million in 2023, then plunged by 111.81% to -$67.2 million in 2024, then fell by 3.23% to -$69.4 million in 2025, then dropped by 6.81% to -$74.1 million in 2026.
- Per Business Quant, the three latest APGE Net Income towards Common Stockholders figures stand at -$74.1 million (Q1 2026), -$69.4 million (Q4 2025), and -$65.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Apogee Therapeutics | 5.53 Bn | 4.47 Bn | - | -74.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -74.11 Mn |
| Dec 31, 2025 | -69.39 Mn |
| Sep 30, 2025 | -65.02 Mn |
| Jun 30, 2025 | -66.10 Mn |
| Mar 31, 2025 | -55.34 Mn |
| Dec 31, 2024 | -67.22 Mn |
| Sep 30, 2024 | -49.02 Mn |
| Jun 30, 2024 | -33.82 Mn |
| Mar 31, 2024 | -32.09 Mn |
| Dec 31, 2023 | -31.74 Mn |
| Sep 30, 2023 | -20.84 Mn |
| Jun 30, 2023 | -18.89 Mn |
| Mar 31, 2023 | -12.53 Mn |
| Dec 31, 2022 | -14.01 Mn |
| Sep 30, 2022 | -19.66 Mn |
| Jun 30, 2022 | -1.82 Mn |